FCD Type II: Altered AKT1, FGF2 [140], and inflammatory mediators (IL1B [141], TLR4, HMGB1, MYD88, and TRAF6 [42]) indicate coordinated activation of growth and immune–gliotic pathways. This evidence concerns the gene TRAF6 and fleck corneal dystrophy.